Picture EBD Group ChinaBio Partnering Forum 2020 Digital Event CBPF2020 650x80
Document › Details

Illumina, Inc.. (3/16/15). "Press Release: Illumina Files Patent Infringement Suit in the United Kingdom Against Premaitha Health plc for Infringement of NIPT Patents". San Diego, CA.

Region Region United Kingdom (GB)
Organisations Organisation Verinata Health Inc.
  Group Illumina (Group)
  Organisation 2 Premaitha Health plc (AIM: NIPT)
  Group Premaitha Health (Group)
Products Product prenatal genetic test
  Product 2 blood test

Illumina, Inc. (NASDAQ:ILMN) today announced that it and its wholly-owned subsidiary, Verinata Health Inc., (together “Illumina”) have filed a patent infringement suit against Premaitha Health plc in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom. Illumina is seeking all available remedies, including damages and injunctive relief.

The patents asserted are European Patent (UK) 0 994 963 B2 and European Patent (UK) 1 981 995 B1, which are exclusively licensed to Illumina from Sequenom, Inc. and The Board of Trustees of Leland Stanford Junior University, respectively. Stanford is joined in the suit as a necessary party because it is the registered owner of the European Patent (UK) 1 981 995 B1. The patents are directed to using cell-free fetal DNA for non-invasive prenatal testing (NIPT). The suit accuses Premaitha’s IONA® Test of infringement, including its use of next-generation sequencing to analyze cell-free fetal DNA from a sample of maternal blood.

“Illumina filed this suit to actively defend its intellectual property rights. We will also continue to monitor the NIPT field and file patent suits where appropriate when our patents are infringed,” said Charles Dadswell, Senior Vice President and General Counsel for Illumina.

About Illumina

Illumina is transforming human health as the global leader in sequencing and array-based technologies. The company serves customers in a broad range of markets, enabling the adoption of genomic solutions in research and clinical settings. To learn how Illumina is unlocking the power of the genome, visit and follow @illumina.

Illumina, Inc.
Rebecca Chambers
Jennifer Temple

Record changed: 2018-09-19


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Illumina (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81

» top